OncoMatch/Clinical Trials/NCT05551299
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Is NCT05551299 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Photosensitizer for hilar cholangiocarcinoma.
Treatment: Photosensitizer — Bile duct cancer is often diagnosed after curative options are no longer available. Stent therapy is used to keep the ducts open and can be combined with photodynamic therapy (PDT) to extend life expectancy. PDT requires an injection of photosensitizer after which light of a particular wavelength is applied endoscopically to kill the cancer cells. Drawbacks include not only high costs and poor availability, but foremost that patients have to avoid direct sunlight for a period of weeks. Radio frequency ablation (RFA) together with stent implantation constitutes an alternative by which the cancer cells are killed through heat, also applied endoscopically. The RFA technology is more widely available and easier to deploy. However, it has not been studied extensively and no randomized trials exist comparing the two methods. This trial will compare survival in patients with a particular bile duct cancer depending on whether they receive PDT or RFA. Moreover, data will be collected on side-effects and quality of life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Cannot have received: photodynamic therapy
Cannot have received: radiofrequency ablation
Lab requirements
Blood counts
Leukopenia (< 2000/mm3); Thrombocytopenia (< 100,000 / mm³); Severe, uncorrected coagulopathy (at the discretion of the physician)
Kidney function
Severely impaired kidney function (at the discretion of the physician)
Liver function
Severely impaired liver function (at the discretion of the physician)
Leukopenia (< 2000/mm3); Thrombocytopenia (< 100,000 / mm³); Severe, uncorrected coagulopathy (at the discretion of the physician); Severely impaired liver and or kidney function (at the discretion of the physician)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify